ABSTRACT:
Background: Unexplained infertility is the absence of identifiable cause for infertility and the female's inability to get pregnant after at least 12 months of unprotected sexual intercourse for whom all the standard evaluations are normal. Objective: Our study aims to assess the effectiveness of adding Cabergoline to Clomiphene citrate in management of women complaining of unexplained infertility.
Materials & Methods: 120 Patients diagnosed with unexplained infertility were randomized to Clomiphene citrate plus cabergoline or Clomiphene citrate alone. All Patients were followed up for three cycles by transvaginal ultrasound folliculometry to document the number and size of mature graffian follicles and ovulation. The primary outcome of the study was the number and size of mature follicles. The secondary outcomes included the occurrence of ovulation, pregnancy rate, abortion rate, endometrial thickness, and the rate of adverse effects of the study medications.
Results: There is a statistically significant difference regarding to the number (P<0.001), size of follicles (P<0.001), occurrence of ovulation (P=0.04, 0.006, 0.016) and endometrial thickness (P=0.000) between the two groups in the favor of adding Cabergoline to Clomiphene citrate.
Conclusion: Adding Cabergoline to Clomiphene citrate in induction of ovulation in euprolactinemic infertile women with unexplained infertility results in high ovulation rate, better endometrial thickness and high pregnancy rate compared to use of Clomiphene citrate alone.